Glaxosmithkline | GSK - Gross Profit On Sales


Glaxosmithkline reported GBP8.75B in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
AbbVie USD 12.54B 474M Mar/2026
Amgen USD 6.89B 415M Dec/2025
AstraZeneca USD 12.61B 225M Mar/2026
Aurora Cannabis CAD 46.62M 14.33M Dec/2025
Bausch Health Companies USD 2B 67M Dec/2025
Bristol-Myers Squibb USD 8.41B 381M Dec/2025
Canopy Growth CAD 21.47M 434K Dec/2025
Corcept Therapeutics USD 162.02M 37.56M Mar/2026
Drreddys Laboratories INR 46.81B 10.24B Dec/2025
Eli Lilly USD 15.92B 1.33B Dec/2025
GlaxoSmithKline GBP 5.75B 429M Mar/2026
Glaxosmithkline GBP 8.75B 2.92B Sep/2025
J&J USD 17.24B 642M Mar/2026
Merck USD 10.85B 2.57B Dec/2025
Novartis USD 10.07B 184M Mar/2026
Pacira USD 126.64M 15.61M Mar/2026
Perrigo USD 325.5M 36.7M Mar/2026
Pfizer USD 11.04B 1.24B Mar/2026
Phibro Animal Health USD 133.5M 12.6M Dec/2025
Prestige Brands USD 157.37M 5.79M Dec/2025
Roche Holding CHF 22.09B 10.04B Dec/2025
Sanofi EUR 8.45B 1.31B Dec/2025
Supernus Pharmaceuticals USD 129.36M 34.68M Mar/2026
Takeda JPY 688.84B 101.71B Mar/2026
Teva Pharmaceutical Industries USD 2.11B 547M Mar/2026
Zoetis USD 1.62B 20M Mar/2026